Late Stage Oncology MCDA Criteria Implementation Results in European Countries: Ukraine Focus

Speaker: Oresta Piniazhko, PhD
Senior lecturer
Danylo Halytsky Lviv National Medical University,
President of ISPOR Ukraine Chapter,
Member of Expert Committee of MoH of Ukraine

ISPOR 20th Annual European Congress: November 7th, 2017, Glasgow

Outline

- Study design background
- MCDA use and cooperation in CEE
- MCDA case study design
- Roadmap of HTA implementation in Ukraine
- Policy implications
- Current challenges and opportunities
Subject to discussion?

- current value assessment
- appraisal approaches of medical technologies using economic evaluation
- informing coverage decisions and improve efficiency in resource allocation


Cooperation in ISPOR CEE Consortium: MCDA research


- Nemeth B., Piniazhko O. MCDA application in CEE: selection of the most important criteria based on examples. ISPOR 19th Annual European Congress, October 29-November 2, 2016, Vienna, Austria. Value in Health. 2016. PHP 180.


1st step: criteria analysis

Overall value of health technology: MCDA criteria selection for case study
### Efficacy

Is this NEW technology superior to standard of care and by how much?

- Much lower
- Lower
- About the same as standard of care
- Higher
- Much higher

### Budg. Imp.

What is the budget impact of this NEW technology vs. standard of care, with the same number of patients treated?

- Significantly higher
- Moderately higher
- No difference
- Moderately lower
- Significantly lower

### Safety

What is the safety profile (side effects and adverse effect) of this NEW technology vs. standard of care?

- Much worse safety profile
- Somewhat worse safety profile
- The same safety profile as standard of care
- Somewhat better safety profile
- Much better safety profile

### Unmet Need

To what extent patients receive provision in relation to their needs in the therapeutic area of NEW technology?

- Far below needs
- Below needs
- Met expectations
- Influential
- Extremely influential

### Strategic

What are strategic/policy implications of reimbursement of NEW technology vs. standard of care?

- Major negative implications
- Moderate negative implications
- Neutral
- Moderate positive implications
- Major positive implications

### Pt. Pref.

What is the patient preference towards this NEW technology vs. standard of care?

- Not preferred at all
- Slightly preferred
- Moderately preferred
- Very much preferred
- Extremely preferred

---

### Median weights on all criteria by all representatives:

**Ukraine case study**

![Ukraine median weights on all criteria by all representatives](image-url)
Physician on all criteria: Ukraine case study

Payer on all criteria: Ukraine case study
Pharmacist on all criteria: Ukraine case study

Implementation of HTA in Ukraine

❖ Project of National Drug Policy until 2025 in Ukraine
❖ Regulations on National list of Essential Medicines and Expert Committee
  *(Order of MOH No.84 dated 12.02.2016)*
❖ Regulation on the selection of drugs for inclusion on the National List of Essential Medicines
  *(Order of MOH No.1050 dated 07.10.2016)*
❖ National List of Essential Medicines
  *(Resolution of Cabinet of Ministers No. 180, dated 16.03.2017)*
❖ Changes of Regulation on the selection of drugs for inclusion on the National List of Essential Medicines
  *(Order of MOH No.885 dated 01.08.2017)*
HTA submissions: challenges and implications

➤ HTA submissions in Ukraine (including CEA and BIA) since 2017
➤ Assessment of submissions: 180 days by Expert Committee
➤ Decisions on inclusion on the list for national procurement programs and reimbursement: 1st results until 1st of July 2018

Legal framework of HTA in Ukraine, 2016-2017

❖ HTA for the inclusion of medicines on the list based on the applied evidence of:
   - quality
   - efficacy
   - effectiveness
   - safety
   - economic evaluation
❖ adhering to the Order of MOH No. 84 dated 11.02.2016 and Order of MOH No. 1050 dated 07.10.2016
Policy implications

- MCDA for priority settings
- HTA for innovative and high-priced medicines, financed by state budget
- Development of national PE guidelines in 2017: globalize the evidence and localize the decisions!
- Implementation of reimbursement programs for cardiovascular diseases, T2D, asthma since April 2017 in Ukraine→ expanding the list by new nosologies in 2017

Conclusions

- High interest to participate and intention to implement the rational and consistent decisions by stakeholders in Ukraine
- Criteria for BIA, unmet need have the highest value for payers
- Importantly, there is a necessity to implement international requirements to HTA, MCDA
- To improve the market access, medicines prescription and patients’ health outcomes in Ukraine
Thank you!

Oresta Piniazhko       orestapb@gmail.com